The potential of granulocyte colony-stimulating factor (G-CSF) to mobilize CD4 cells and/or CD34 cells for use in gene therapy or to support antiretroviral therapy was examined. Ten human immunodeficiency virus -infected patients were treated with G-CSF (300 mg/day) for 5 days. Numbers of CD4 and CD34 cells were measured. To examine the numbers of naive and memory type CD4 cells, CD4 cell coexpression of CD45RA and CD45RO was measured. Functionality of mobilized CD4 cells was examined by use of the proliferation assay and interleukin-2 ELISA. The number of CD34 cells increased from 1.50 to 20.01/mL (P õ .002). The CD4 cell count increased from 236 to 452/mL (P õ .002). The CD45RA/CD45RO ratio increased from 0.50 to 0.57 (P õ .03). Mobilized CD4 cells were functionally intact. In conclusion, G-CSF induced increases in numbers of CD34 cells and CD4 cells in HIV-infected patients. Furthermore, the fraction of naive CD4 cells increased. These findings have implications for the design of immunotherapy or gene therapy protocols.
Granulocyte colony-stimulating factor (G-CSF) is a hemato-(HIV) -infected patients [1 -4] . In the present study, we examined whether G-CSF might be useful in gene therapy or to poietic growth factor that increases the numbers of circulating hematopoietic progenitor cells (CD34 cells) and CD4-positive support antiretroviral treatment. The G-CSF -induced increase in numbers of CD34 cells and CD4 cells in HIV-infected pa-T lymphocytes (CD4 cells) in human immunodeficiency virus tients was examined. CD4 cell coexpression of CD45RA and CD45RO was used to characterize mobilized CD4 cells as naive and memory cells, respectively. Furthermore, the functionality of mobilized CD4 cells was examined. treatment, blood samples were collected during G-CSF treatment used to quantitate IL-2 production. The assay was done according to the instructions of the manufacturer. Results are reported as (days 0-4) and on the following 4 days (days 5-8). Blood collected in tubes containing EDTA was used to obtain a full blood IL-2 production in response to PHA stimulation minus response to plain culture medium. All results are medians of values from cell count and for flow cytometry. On days 06, 03, 0, 4, and 8, additional blood samples were drawn into tubes containing heparin duplicate cultures.
Measurements of virus load.
To determine virus load, quantito obtain peripheral blood mononuclear cells (PBMC) by means of density gradient centrifugation.
fication of viral RNA in plasma was done with a polymerase chain reaction quantitative kit (Amplicor Monitor HIV-1 PCR; Roche, Flow cytometry. Flow cytometric analyses were done as described [4] . The fluorescence of 5000 cells (lymphocyte subsets) Branchburg, NJ) according to the instructions of the manufacturer. Plasma was obtained after centrifugation at 400 g for 7 min, haror 50,000 cells (CD34 and isotype controls) was measured. To determine the absolute numbers of CD34 cells and lymphocytes vested, and immediately stored at 070ЊC until use. Statistical analysis. Data points obtained from multiple experiin peripheral blood, the percentage of the cells expressing CD34 was multiplied by the white blood cell count, while the percentage ments were reported as means ({SEs). Significance levels were determined by Student's t test analysis. For comparisons within of cells expressing CD3, CD4, and CD8 in a lymphocyte gate was multiplied by the lymphocyte count. The following combinations the group, we used a paired-sample t test. of monoclonal antibodies were used to determine phenotypes: isotype control; CD3 (Leu-4, SK7), CD4 (Leu-3a, SK3), CD8 (LeuResults 2a, SK1); CD4 (Leu-3a, SK3), CD45RA (Leu-18, L48), CD45RO (Leu-45RO, UCHL-1); CD4 (Leu-3a, SK3), CD25 (2A3), CD69
G-CSF effect on the absolute numbers of CD34 and CD4
(Leu-23, L78); CD34 (anti-HPCA-2). All monoclonal antibodies cells. The absolute number of circulating CD34 cells inwere purchased from Becton Dickinson (San Jose, CA).
creased significantly during G-CSF treatment ( figure 1A) . On Proliferation assay. On days 06, 03, 0, 4, and 8, PBMC were day 0, the mean number of CD34 cells was 1.50/mL ({0.11).
used for proliferation assay, done essentially as described [5] . Cell On day 2, the number of CD34 cells had increased significantly No evidence of peripheral proliferation. To evaluate if CD4 cells were generated by peripheral proliferation, we measured CD4 cells coexpressing the activation antigens CD69 and CD25. On day 0, 12.4% ({5.5) of CD4 cells expressed CD69, and on day 4 this fraction was reduced to 9.3% ({5.6) (P õ .04). In contrast, no differences were found between values for day 0 and day 06, 03, or 8. Furthermore, on day 0 we found that 13.0% ({3.6) of CD4 cells coexpressed CD25. This fraction was not different from the fractions we found on any other day.
Functionality of mobilized CD4 cells. The functionality of CD4 cells was examined by use of a proliferation assay. All patients responded to PHA, with a mean proliferative response of 110.7 1 10 3 cpm on day 0. There were no significant differences between proliferative responses on day 0 and on any other day. In addition, the functionality of the CD4 cells was evaluated by IL-2 production. On day 0, PBMC from 7 patients produced IL-2 in response to stimulation with PHA (mean, 33 pg/mL [{14]). On day 4, PBMC from 8 patients produced IL-2 in response to PHA (mean, 81 pg/mL [{59]). However, no significant differences in IL-2 production in response to PHA were found. Thus, the CD4 cells mobilized by G-CSF treatment appear to have normal functionality.
Virus load during G-CSF therapy. Virus load during number per milliliter, in 3 patients the copy number was õ200 on day 0 as well as on day 4, and in 1 patient there was a decrease in virus load. On day 0, the mean copy number was initiation of G-CSF treatment, at 452/mL ({52, P õ .002). Interestingly, although there was a decrease in CD4 cell count 12,885/mL ({7421), and on day 4 it was 16,993 ({11,116). Thus, we found a minor increase in virus load. This increase, during the rest of the study period, it did not return to baseline ( figure 1B) . Thus, the CD4 cell count was 323/mL on day 8 however, was not significant (P Å .47). ({38, P õ .02). For all 10 patients, we found the CD4 cell count to increase by at least 100/mL. The increase in CD4 cell Discussion count was mainly due to an increase in lymphocyte count from 2.26 1 10 9 /L ({0.38) to 3.28 1 10 9 /L ({0.48).
This study demonstrates that G-CSF increases both CD34 and CD4 cells in HIV-infected persons. Furthermore, we found Increase in CD45RA/CD45RO ratio. To evaluate the numbers of naive and memory-type CD4 cells, we measured CD4 an increase in percentage of naive CD4 cells. These data make G-CSF a candidate for use in gene therapy or to support antiretcells coexpressing CD45RA and CD45RO. On day 0, the mean percentage of CD4 cells expressing CD45RA and CD45RO roviral therapy. Three events might explain the rise in CD4 cell count: was 31.2% ({3.6) and 68.1% ({3.7), respectively. CD45RA and CD45RO values on day 4 were 33.4% ({3.9) and 65.8% differentiation of CD34 cells, peripheral proliferation, and redistribution of CD4 cells from the lymphatics. Studies in ({4.2). The increase in percentage of CD45RA cells was significant, as was the decrease in CD45RO cells (P õ .01). The mice have shown that naive CD4 cells exported from the thymus express CD45RA. By contrast, memory CD4 cells mean CD45RA/CD45RO ratio was 0.50 on day 0, and the ratio increased significantly to 0.57 on day 4 and 0.61 on day 8 (P derived from peripheral proliferation express CD45RO [6] . However, interconversion between CD45RA and CD45RO õ .03). In contrast, no significant differences were found to exist between ratios on day 0 and day 06 or 03. Although the has been demonstrated [7] , suggesting that isoform expres-sion may not reflect a unidirectional maturation from naive cells. These findings have implications for the design of gene therapy protocols. to memory type cells. Thus, the rise in CD45RA/CD45RO ratio does support differentiation of CD34 cells but does not provide definite proof. The rapid increase in CD4 cell
